Reply to L. Dal Maso et al.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

2 citing papers in PubMed.

1. Impact of multi-agent systemic therapy on all-cause and disease-specific survival for people living with HIV who are diagnosed with non-Hodgkin lymphoma: population-based analyses from the state of Georgia.Leukemia & lymphoma · 2023
   Article
2. Survival Deficit for HIV-Infected Lymphoma Patients in the National Cancer Database.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2017
   Article

Corrections and comments

• Comment on
  Elevated Cancer-Specific Mortality Among HIV-Infected Patients in the United States.2015
• Comment on
  All-Cause and Cancer-Specific Mortality Among Patients With Cancer Infected or Not Infected With HIV.2016

Authors and funding

4 authors.

Funding

Abstract

PubMed holds no abstract for this paper.

Indexed as